Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors. [PDF]
Shao H, Shi L, Fonseca VA.
europepmc +1 more source
Multicentre quality improvement initiative to improve patient education and safety in the prescription of Sodium-Glucose transporter 2 inhibitors. [PDF]
Saad L +6 more
europepmc +1 more source
Sodium-glucose transporter 2 inhibitors and cardiovascular-kidney-metabolic syndrome: a narrative review. [PDF]
Wang Y, Wang Y, He X, Li X.
europepmc +1 more source
Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors. [PDF]
Chung CJ +7 more
europepmc +1 more source
Effects of different dosages of Sodium-Glucose Transporter 2 Inhibitors on lipid levels in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. [PDF]
Cai T, Gao Y, Zhang L, Yang T, Chen Q.
europepmc +1 more source
Long-term effects of metformin versus sodium glucose transporter 2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes. [PDF]
Hao X, Cui J, Zhang M, Zhang D.
europepmc +1 more source
Comparative efficacy of sodium-glucose transporter 2 inhibitors on lipid profiles in nonalcoholic fatty liver disease (NAFLD): a comprehensive Bayesian network meta-analysis. [PDF]
Khalil I +3 more
europepmc +1 more source
Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes. [PDF]
Piccirillo F +7 more
europepmc +1 more source
Effectiveness of Sodium-Glucose Transporter 2 Inhibitors and Semaglutide on Body Composition in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Real-World Cohort Study with Bioelectrical Impedance Analysis. [PDF]
Yang Q +9 more
europepmc +1 more source
The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium-Glucose Transporter 2 Inhibitors. [PDF]
Yamato M, Kato N, Yamada KI, Inoguchi T.
europepmc +1 more source

